Pregnancy in Women with Atypical Hemolytic Uremic Syndrome

Details

Serval ID
serval:BIB_4AC480849F5B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Pregnancy in Women with Atypical Hemolytic Uremic Syndrome
Journal
Nephron
Author(s)
Rondeau E., Ardissino G., Caby-Tosi M. P., Al-Dakkak I., Fakhouri F., Miller B., Scully M., H. U. S. Registry HUS
ISSN
2235-3186 (Electronic)
ISSN-L
1660-8151
Publication state
Published
Issued date
2022
Volume
146
Number
1
Pages
1-10
Language
english
Notes
Rondeau, Eric
Ardissino, Gianluigi
Caby-Tosi, Marie-Pierre
Al-Dakkak, Imad
Fakhouri, Fadi
Miller, Benjamin
Scully, Marie
eng
Switzerland
Nephron. 2022;146(1):1-10. doi: 10.1159/000518171. Epub 2021 Sep 7.
Abstract
BACKGROUND: Pregnancy outcomes in patients with atypical hemolytic uremic syndrome (aHUS) are not well-documented. Here, we present characteristics of and outcomes for patients with aHUS who became pregnant while enrolled in the Global aHUS Registry. METHODS: The observational Global aHUS Registry (NCT01522183), initiated in April 2012, collects demographics, disease history, treatment, and outcomes data for patients with aHUS, regardless of treatment approach. This descriptive analysis includes patients from the Registry with evaluable pregnancy data supplemented with pharmacovigilance information; the number of pregnancies, outcomes, and exposure to eculizumab were evaluated. RESULTS: As of April 1, 2019, 44 pregnancies were recorded in 41 patients, with 24 pregnancies exposed to eculizumab. Pathogenic variants were identified in 48.8% of patients. Three patients were on dialysis and 6 patients had a kidney graft at the time of pregnancy. Excluding elective terminations, 85.3% of pregnancies resulted in live births. Elective terminations were recorded in 22.7% of pregnancies, miscarriages occurred in 9.1% of pregnancies, and late fetal death in 2.3% of pregnancies. No malformations or anomalies were reported. CONCLUSIONS: Our results show that in women with aHUS, even on dialysis or with a kidney graft, pregnancy is possible with careful monitoring for aHUS flares and prematurity. Prophylactic or therapeutic eculizumab offers disease control with low-risk of fetal abnormalities.
Keywords
*Atypical hemolytic uremic syndrome, *Eculizumab, *Pregnancy, *Real-world evidence, *Registry
Pubmed
Create date
01/03/2022 10:17
Last modification date
02/03/2022 6:35
Usage data